Process / pipelineClinical scoring
CHA₂DS₂-VASc 评分
CHA₂DS₂-VASc 评分由 Lip、Nieuwlaat 及同事于 2010 年开发，是一个 9 分的风险分层工具，用于预测房颤患者的年度卒中和全身栓塞风险。它是主要心脏病学指南推荐用于指导抗凝决策的评分。
在 MethodMind 中打开即将推出Apply, compare, get guidance
Tools & resources
Learn & explore
视频即将推出
阅读完整方法
仅限会员
登录使用免费账户登录即可阅读本节。
方法图谱
相关方法的邻域——选择一个节点以展开探索。
来源
- Lip, G. Y., Nieuwlaat, R., Pisters, R., Lane, D. A., & Crijns, H. J. (2010). Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest, 137(2), 263-272. DOI: 10.1378/chest.09-1584 ↗
- Pisters, R., Lane, D. A., Nieuwlaat, R., de Vos, C. B., Crijns, H. J., & Lip, G. Y. (2012). A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest, 138(5), 1093-1100. DOI: 10.1378/chest.10-0134 ↗
如何引用本页
ScholarGate. (2026, June 3). Congestive heart failure, Hypertension, Age ≥75, Diabetes, Stroke/TIA/thromboembolism (doubled), Vascular disease, Age 65-74, Sex category (female) Score. ScholarGate. https://scholargate.app/zh/clinical-assessment/cha2ds2-vasc
选用哪种方法？
将本方法与其最相近的同类并置，并排研读——本馆将书籍铺陈于案上，取舍则由您定夺。
并排比较 →